{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:55Z","timestamp":1790245615542,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":396,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Major Basic Research Projects of Jiangxi Province","award":["20143ACB20005"],"award-info":[{"award-number":["20143ACB20005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSF)","doi-asserted-by":"publisher","award":["81260231"],"award-info":[{"award-number":["81260231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSF)","doi-asserted-by":"publisher","award":["81760033"],"award-info":[{"award-number":["81760033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Graduate Student Innovation Fund of Jiangxi Province","award":["YC2014-B023"],"award-info":[{"award-number":["YC2014-B023"]}]},{"name":"Jiangxi Provincial Health and Family Planning Commission Science and Technology Program","award":["20155645"],"award-info":[{"award-number":["20155645"]}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1074\/jbc.ra119.008037","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T20:55:42Z","timestamp":1561409742000},"page":"12167-12179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Bone marrow\u2013derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway"],"prefix":"10.1016","volume":"294","author":[{"given":"Xiaoyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.RA119.008037_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.RA119.008037_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1074\/jbc.RA119.008037_bib3","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst"},{"key":"10.1074\/jbc.RA119.008037_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.RA119.008037_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.RA119.008037_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.RA119.008037_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.29745","article-title":"Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"10.1074\/jbc.RA119.008037_bib8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","article-title":"Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors","volume":"10","author":"Eide","year":"2015","journal-title":"Curr. Hematol. Malig. Rep"},{"key":"10.1074\/jbc.RA119.008037_bib10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1074\/jbc.RA119.008037_bib12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"J. Natl. Cancer Inst"},{"key":"10.1074\/jbc.RA119.008037_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib15","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.RA119.008037_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1074\/jbc.RA119.008037_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.RA119.008037_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the Dasatinib discontinuation trial in patients with chronic myeloid leukemia who received Dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1074\/jbc.RA119.008037_bib19","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","article-title":"Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile","volume":"119","author":"Parker","year":"2012","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib20","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem. Pharmacol"},{"key":"10.1074\/jbc.RA119.008037_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1074\/jbc.RA119.008037_bib23","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1007\/s13277-014-2610-9","article-title":"New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia","volume":"35","author":"Shahrabi","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1074\/jbc.RA119.008037_bib24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.1588607","article-title":"Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia","volume":"21","author":"Williams","year":"2007","journal-title":"Genes Dev"},{"key":"10.1074\/jbc.RA119.008037_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1087057113501081","article-title":"A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia","volume":"19","author":"Singh","year":"2014","journal-title":"J. Biomol. Screen"},{"key":"10.1074\/jbc.RA119.008037_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs. imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib28","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"key":"10.1074\/jbc.RA119.008037_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol. Cancer Res"},{"key":"10.1074\/jbc.RA119.008037_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/leu.2011.291","article-title":"Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn\/CXCR4 interactions in lipid rafts","volume":"26","author":"Tabe","year":"2012","journal-title":"Leukemia"},{"key":"10.1074\/jbc.RA119.008037_bib32","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt\u2013\u03b2-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells nonselectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"key":"10.1074\/jbc.RA119.008037_bib34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells","volume":"7","author":"Weisberg","year":"2008","journal-title":"Mol. Cancer Ther"},{"key":"10.1074\/jbc.RA119.008037_bib35","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA119.008037_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","article-title":"Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia","volume":"38","author":"Quintarelli","year":"2014","journal-title":"Leuk. Res"},{"key":"10.1074\/jbc.RA119.008037_bib37","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib38","doi-asserted-by":"crossref","first-page":"e1065368","DOI":"10.1080\/2162402X.2015.1065368","article-title":"Interferon \u03b3 modulates sensitivity of CML cells to tyrosine kinase inhibitors","volume":"5","author":"Held","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1074\/jbc.RA119.008037_bib39","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/blood-2015-10-673087","article-title":"MIP-1\u03b1\/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice","volume":"127","author":"Baba","year":"2016","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/eji.200425822","article-title":"The role of Notch and IL-7 signaling in early thymocyte proliferation and differentiation","volume":"35","author":"Balciunaite","year":"2005","journal-title":"Eur. J. Immunol"},{"key":"10.1074\/jbc.RA119.008037_bib41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.smim.2012.02.005","article-title":"IL-7 in human health and disease","volume":"24","author":"Lundstr\u00f6m","year":"2012","journal-title":"Semin. Immunol"},{"key":"10.1074\/jbc.RA119.008037_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cyto.2012.06.022","article-title":"Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin 7","volume":"60","author":"Bortolin","year":"2012","journal-title":"Cytokine"},{"key":"10.1074\/jbc.RA119.008037_bib43","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/eji.201040404","article-title":"Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling","volume":"40","author":"Mumprecht","year":"2010","journal-title":"Eur. J. Immunol"},{"key":"10.1074\/jbc.RA119.008037_bib44","first-page":"47","article-title":"Notch1 and IL-7 receptor signalling in early T-cell development and leukaemia","volume":"360","author":"Gonz\u00e1lez-Garc\u00eda","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol"},{"key":"10.1074\/jbc.RA119.008037_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood.V78.3.753.753","article-title":"Human interleukin 7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias","volume":"78","author":"Digel","year":"1991","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib46","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.RA119.008037_bib47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI81468","article-title":"LNK\/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors","volume":"126","author":"Cheng","year":"2016","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.RA119.008037_bib48","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood.V75.11.2097.2097","article-title":"Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia","volume":"75","author":"Touw","year":"1990","journal-title":"Blood"},{"key":"10.1074\/jbc.RA119.008037_bib49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2011.56","article-title":"Intracellular reactive oxygen species are essential for PI3K\/Akt\/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells","volume":"25","author":"Silva","year":"2011","journal-title":"Leukemia"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820301666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820301666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.RA119.008037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T22:54:54Z","timestamp":1641250494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820301666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":49,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0021925820301666"],"URL":"https:\/\/doi.org\/10.1074\/jbc.ra119.008037","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow\u2013derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.RA119.008037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Zhang et al.","name":"copyright","label":"Copyright"}]}}